David Esposito is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers. As the CEO of Armune BioScience, he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.